Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2022-01, Vol.31 (1), p.230-235
Hauptverfasser: Yu, Yi-Chuan, Luu, Hung N, Wang, Renwei, Thomas, Claire E, Glynn, Nancy W, Youk, Ada O, Behari, Jaideep, Yuan, Jian-Min
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 235
container_issue 1
container_start_page 230
container_title Cancer epidemiology, biomarkers & prevention
container_volume 31
creator Yu, Yi-Chuan
Luu, Hung N
Wang, Renwei
Thomas, Claire E
Glynn, Nancy W
Youk, Ada O
Behari, Jaideep
Yuan, Jian-Min
description Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epidemiologic data on iron overload without hemochromatosis in relation to HCC are sparse. This study aimed to examine the associations between serum biomarkers of iron and the risk of HCC in patients with NAFLD. We identified 18,569 patients with NAFLD using the University of Pittsburgh Medical Center electronic health records from 2004 through 2018. After an average 4.34 years of follow-up, 244 patients developed HCC. Cox proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of HCC incidence associated with elevated levels of iron biomarkers with adjustment for age, sex, race, body mass index, history of diabetes, and tobacco smoking. The HRs (95% CIs) of HCC for clinically defined elevation of serum iron and transferrin saturation were 2.91 (1.34-6.30) and 2.02 (1.22-3.32), respectively, compared with their respective normal range. No statistically significant association was observed for total iron-binding capacity or serum ferritin with HCC risk. Elevated levels of serum iron and transferrin saturation were significantly associated with increased risk of HCC among patients with NAFLD without hemochromatosis or other major underlying causes of chronic liver diseases. Clinical surveillance of serum iron level may be a potential strategy to identify patients with NAFLD who are at high risk for HCC.
doi_str_mv 10.1158/1055-9965.EPI-21-0754
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2582815013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2582815013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-521d3941cdf1254cbc38a3d448f650e9a76b281d7018be1fc2675bcd29edd98d3</originalsourceid><addsrcrecordid>eNo9kEtP3TAQRq2qVXn-BCovuwnYcSaxl-3ldaUrigqsLceeCEMS39oOiG1_OYl4rGY0-s6M5hByxNkx5yBPOAMolKrh-Ox6XZS8YA1UX8guByGLpgH4OvcfmR2yl9IDY6xRAN_JjqjqSimQu-T_DcZpoL99GEx8xJho6Og6hpHeZJOnRM3o6F-fHpf5JW5NDhb7fupNpCsTrR9nkJ7iE_ZhO-CYqR_ptcl-bhN99vmeXoXR9Dbch95bem5yfqEb_4SRnvqEJuEB-daZPuHhe90nd-dnt6vLYvPnYr36tSmsgDoXUHInVMWt63gJlW2tkEa4qpJdDQyVaeq2lNw1jMsWeWfLuoHWulKhc0o6sU9-vu3dxvBvwpT14NPyjBkxTEmXIGceGBdzFN6iNoaUInZ6G_0s6EVzphf9elGrF7V61q9Lrhf9M_fj_cTUDug-qQ_f4hXd8ILU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582815013</pqid></control><display><type>article</type><title>Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>Yu, Yi-Chuan ; Luu, Hung N ; Wang, Renwei ; Thomas, Claire E ; Glynn, Nancy W ; Youk, Ada O ; Behari, Jaideep ; Yuan, Jian-Min</creator><creatorcontrib>Yu, Yi-Chuan ; Luu, Hung N ; Wang, Renwei ; Thomas, Claire E ; Glynn, Nancy W ; Youk, Ada O ; Behari, Jaideep ; Yuan, Jian-Min</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epidemiologic data on iron overload without hemochromatosis in relation to HCC are sparse. This study aimed to examine the associations between serum biomarkers of iron and the risk of HCC in patients with NAFLD. We identified 18,569 patients with NAFLD using the University of Pittsburgh Medical Center electronic health records from 2004 through 2018. After an average 4.34 years of follow-up, 244 patients developed HCC. Cox proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of HCC incidence associated with elevated levels of iron biomarkers with adjustment for age, sex, race, body mass index, history of diabetes, and tobacco smoking. The HRs (95% CIs) of HCC for clinically defined elevation of serum iron and transferrin saturation were 2.91 (1.34-6.30) and 2.02 (1.22-3.32), respectively, compared with their respective normal range. No statistically significant association was observed for total iron-binding capacity or serum ferritin with HCC risk. Elevated levels of serum iron and transferrin saturation were significantly associated with increased risk of HCC among patients with NAFLD without hemochromatosis or other major underlying causes of chronic liver diseases. Clinical surveillance of serum iron level may be a potential strategy to identify patients with NAFLD who are at high risk for HCC.</description><identifier>ISSN: 1055-9965</identifier><identifier>ISSN: 1538-7755</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-21-0754</identifier><identifier>PMID: 34649958</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Female ; Humans ; Iron - blood ; Liver Neoplasms - blood ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease - blood ; Pennsylvania ; Retrospective Studies ; Risk ; Transferrin - metabolism</subject><ispartof>Cancer epidemiology, biomarkers &amp; prevention, 2022-01, Vol.31 (1), p.230-235</ispartof><rights>2021 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-521d3941cdf1254cbc38a3d448f650e9a76b281d7018be1fc2675bcd29edd98d3</citedby><cites>FETCH-LOGICAL-c356t-521d3941cdf1254cbc38a3d448f650e9a76b281d7018be1fc2675bcd29edd98d3</cites><orcidid>0000-0003-2265-0162 ; 0000-0001-6912-9759 ; 0000-0001-9515-3277 ; 0000-0002-2172-1849 ; 0000-0002-4620-3108</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34649958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Yi-Chuan</creatorcontrib><creatorcontrib>Luu, Hung N</creatorcontrib><creatorcontrib>Wang, Renwei</creatorcontrib><creatorcontrib>Thomas, Claire E</creatorcontrib><creatorcontrib>Glynn, Nancy W</creatorcontrib><creatorcontrib>Youk, Ada O</creatorcontrib><creatorcontrib>Behari, Jaideep</creatorcontrib><creatorcontrib>Yuan, Jian-Min</creatorcontrib><title>Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease</title><title>Cancer epidemiology, biomarkers &amp; prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epidemiologic data on iron overload without hemochromatosis in relation to HCC are sparse. This study aimed to examine the associations between serum biomarkers of iron and the risk of HCC in patients with NAFLD. We identified 18,569 patients with NAFLD using the University of Pittsburgh Medical Center electronic health records from 2004 through 2018. After an average 4.34 years of follow-up, 244 patients developed HCC. Cox proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of HCC incidence associated with elevated levels of iron biomarkers with adjustment for age, sex, race, body mass index, history of diabetes, and tobacco smoking. The HRs (95% CIs) of HCC for clinically defined elevation of serum iron and transferrin saturation were 2.91 (1.34-6.30) and 2.02 (1.22-3.32), respectively, compared with their respective normal range. No statistically significant association was observed for total iron-binding capacity or serum ferritin with HCC risk. Elevated levels of serum iron and transferrin saturation were significantly associated with increased risk of HCC among patients with NAFLD without hemochromatosis or other major underlying causes of chronic liver diseases. Clinical surveillance of serum iron level may be a potential strategy to identify patients with NAFLD who are at high risk for HCC.</description><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Iron - blood</subject><subject>Liver Neoplasms - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non-alcoholic Fatty Liver Disease - blood</subject><subject>Pennsylvania</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Transferrin - metabolism</subject><issn>1055-9965</issn><issn>1538-7755</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtP3TAQRq2qVXn-BCovuwnYcSaxl-3ldaUrigqsLceeCEMS39oOiG1_OYl4rGY0-s6M5hByxNkx5yBPOAMolKrh-Ox6XZS8YA1UX8guByGLpgH4OvcfmR2yl9IDY6xRAN_JjqjqSimQu-T_DcZpoL99GEx8xJho6Og6hpHeZJOnRM3o6F-fHpf5JW5NDhb7fupNpCsTrR9nkJ7iE_ZhO-CYqR_ptcl-bhN99vmeXoXR9Dbch95bem5yfqEb_4SRnvqEJuEB-daZPuHhe90nd-dnt6vLYvPnYr36tSmsgDoXUHInVMWt63gJlW2tkEa4qpJdDQyVaeq2lNw1jMsWeWfLuoHWulKhc0o6sU9-vu3dxvBvwpT14NPyjBkxTEmXIGceGBdzFN6iNoaUInZ6G_0s6EVzphf9elGrF7V61q9Lrhf9M_fj_cTUDug-qQ_f4hXd8ILU</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Yu, Yi-Chuan</creator><creator>Luu, Hung N</creator><creator>Wang, Renwei</creator><creator>Thomas, Claire E</creator><creator>Glynn, Nancy W</creator><creator>Youk, Ada O</creator><creator>Behari, Jaideep</creator><creator>Yuan, Jian-Min</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2265-0162</orcidid><orcidid>https://orcid.org/0000-0001-6912-9759</orcidid><orcidid>https://orcid.org/0000-0001-9515-3277</orcidid><orcidid>https://orcid.org/0000-0002-2172-1849</orcidid><orcidid>https://orcid.org/0000-0002-4620-3108</orcidid></search><sort><creationdate>202201</creationdate><title>Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease</title><author>Yu, Yi-Chuan ; Luu, Hung N ; Wang, Renwei ; Thomas, Claire E ; Glynn, Nancy W ; Youk, Ada O ; Behari, Jaideep ; Yuan, Jian-Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-521d3941cdf1254cbc38a3d448f650e9a76b281d7018be1fc2675bcd29edd98d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Iron - blood</topic><topic>Liver Neoplasms - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non-alcoholic Fatty Liver Disease - blood</topic><topic>Pennsylvania</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Transferrin - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Yi-Chuan</creatorcontrib><creatorcontrib>Luu, Hung N</creatorcontrib><creatorcontrib>Wang, Renwei</creatorcontrib><creatorcontrib>Thomas, Claire E</creatorcontrib><creatorcontrib>Glynn, Nancy W</creatorcontrib><creatorcontrib>Youk, Ada O</creatorcontrib><creatorcontrib>Behari, Jaideep</creatorcontrib><creatorcontrib>Yuan, Jian-Min</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Yi-Chuan</au><au>Luu, Hung N</au><au>Wang, Renwei</au><au>Thomas, Claire E</au><au>Glynn, Nancy W</au><au>Youk, Ada O</au><au>Behari, Jaideep</au><au>Yuan, Jian-Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease</atitle><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2022-01</date><risdate>2022</risdate><volume>31</volume><issue>1</issue><spage>230</spage><epage>235</epage><pages>230-235</pages><issn>1055-9965</issn><issn>1538-7755</issn><eissn>1538-7755</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to the rising incidence of hepatocellular carcinoma (HCC) in the United States and other developed countries. Iron, an essential metal primarily stored in hepatocytes, may play a role in the development of NAFLD-related HCC. Epidemiologic data on iron overload without hemochromatosis in relation to HCC are sparse. This study aimed to examine the associations between serum biomarkers of iron and the risk of HCC in patients with NAFLD. We identified 18,569 patients with NAFLD using the University of Pittsburgh Medical Center electronic health records from 2004 through 2018. After an average 4.34 years of follow-up, 244 patients developed HCC. Cox proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) of HCC incidence associated with elevated levels of iron biomarkers with adjustment for age, sex, race, body mass index, history of diabetes, and tobacco smoking. The HRs (95% CIs) of HCC for clinically defined elevation of serum iron and transferrin saturation were 2.91 (1.34-6.30) and 2.02 (1.22-3.32), respectively, compared with their respective normal range. No statistically significant association was observed for total iron-binding capacity or serum ferritin with HCC risk. Elevated levels of serum iron and transferrin saturation were significantly associated with increased risk of HCC among patients with NAFLD without hemochromatosis or other major underlying causes of chronic liver diseases. Clinical surveillance of serum iron level may be a potential strategy to identify patients with NAFLD who are at high risk for HCC.</abstract><cop>United States</cop><pmid>34649958</pmid><doi>10.1158/1055-9965.EPI-21-0754</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2265-0162</orcidid><orcidid>https://orcid.org/0000-0001-6912-9759</orcidid><orcidid>https://orcid.org/0000-0001-9515-3277</orcidid><orcidid>https://orcid.org/0000-0002-2172-1849</orcidid><orcidid>https://orcid.org/0000-0002-4620-3108</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1055-9965
ispartof Cancer epidemiology, biomarkers & prevention, 2022-01, Vol.31 (1), p.230-235
issn 1055-9965
1538-7755
1538-7755
language eng
recordid cdi_proquest_miscellaneous_2582815013
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research
subjects Aged
Biomarkers, Tumor - blood
Carcinoma, Hepatocellular - blood
Female
Humans
Iron - blood
Liver Neoplasms - blood
Male
Middle Aged
Non-alcoholic Fatty Liver Disease - blood
Pennsylvania
Retrospective Studies
Risk
Transferrin - metabolism
title Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A54%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Biomarkers%20of%20Iron%20Status%20and%20Risk%20of%20Hepatocellular%20Carcinoma%20Development%20in%20Patients%20with%20Nonalcoholic%20Fatty%20Liver%20Disease&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=Yu,%20Yi-Chuan&rft.date=2022-01&rft.volume=31&rft.issue=1&rft.spage=230&rft.epage=235&rft.pages=230-235&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/10.1158/1055-9965.EPI-21-0754&rft_dat=%3Cproquest_cross%3E2582815013%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2582815013&rft_id=info:pmid/34649958&rfr_iscdi=true